MedTrace Logo

A Clinical Trial to Evaluate the Efficacy and Safety of HL-1186 Tablet in the Treatment of Postherpetic Neuralgia

NCT07758920 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2026-08-11

No results posted yet for this study

Summary

This is a multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled, parallel-group trial to evaluate the safety, efficacy and pharmacokinetic (PK) profile of HL-1186 Tablet in patients with postherpetic neuralgia (PHN).

Conditions

  • Postherpetic Neuralgia ( PHN )

Interventions

DRUG

HL-1186

HL-1186 tablet for oral administration

DRUG

HL-1186 placebo

HL-1186 placebo tablet for oral administration

DRUG

Pregabalin capsule

Pregabalin capsule for oral administration

DRUG

Pregabalin capsule placebo

Pregabalin capsule placebo for oral administration

Sponsors & Collaborators

  • Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-31
Primary Completion
2027-06-30
Completion
2027-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07758920 on ClinicalTrials.gov